Atrion (ATRI) Stock Forecast, Price & News

Atrion's stock was trading at $559.45 at the beginning of 2023. Since then, ATRI shares have increased by 0.4% and is now trading at $561.80.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ATRI earnings forecast.

Atrion Co. (NASDAQ:ATRI) issued its earnings results on Friday, November, 1st. The medical instruments supplier reported $5.15 earnings per share for the quarter. The medical instruments supplier had revenue of $38.88 million for the quarter. Atrion had a net margin of 17.01% and a trailing twelve-month return on equity of 12.36%.

Atrion announced a quarterly dividend on Tuesday, May 23rd. Investors of record on Thursday, June 15th will be given a dividend of $2.15 per share on Friday, June 30th. This represents a $8.60 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date is Wednesday, June 14th.
Read our dividend analysis for ATRI.

ETFs with the largest weight of Atrion (NASDAQ:ATRI) stock in their portfolio include Small Cap US Equity Select ETF (RNSC), ProShares Russell 2000 Dividend Growers ETF (SMDV), SPDR S&P Health Care Equipment ETF (XHE), Royce Quant Small-Cap Quality Value ETF (SQLV), Timothy Plan US Small Cap Core ETF (TPSC), iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), Vanguard U.S. Quality Factor ETF (VFQY) and Hartford Multifactor Small Cap ETF (ROSC).

Atrion (NASDAQ:ATRI) pays an annual dividend of $8.60 per share and currently has a dividend yield of 1.54%. The company has been increasing its dividend for 19 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 51.13%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for ATRI.

1 employees have rated Atrion Chief Executive Officer David A. Batta on Glassdoor.com. David A. Batta has an approval rating of 100% among the company's employees. This puts David A. Batta in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Atrion to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Atrion investors own include International Paper (IP), AT&T (T), WestRock (WRK), AbbVie (ABBV), Caterpillar (CAT), Eastman Chemical (EMN), Gilead Sciences (GILD), Altria Group (MO), Pfizer (PFE) and Philip Morris International (PM).

Atrion trades on the NASDAQ under the ticker symbol "ATRI."

Atrion's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (11.66%), Neuberger Berman Group LLC (10.88%), BlackRock Inc. (6.16%), Dimensional Fund Advisors LP (2.95%), State Street Corp (1.96%) and Boston Trust Walden Corp (1.81%). Insiders that own company stock include Emile A Battat and Jeffery Strickland.
View institutional ownership trends.

Shares of ATRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRI stock can currently be purchased for approximately $561.80.

Atrion (NASDAQ:ATRI) has a market capitalization of $988.77 million and generates $183.51 million in revenue each year. The medical instruments supplier earns $35.01 million in net income (profit) each year or $16.82 on an earnings per share basis.

The company employs 667 workers across the globe.

Atrion's mailing address is ONE ALLENTOWN PARKWAY, ALLEN TX, 75002. The official website for the company is www.atrioncorp.com. The medical instruments supplier can be reached via phone at (972) 390-9800, via email at ir-info@atrioncorp.com, or via fax at 972-396-7581.